New Tools Not Inspi...
Health Care: Drugs
Vivus (VVUS: NASDAQ)
$14.01 0.20 | 1.45%
06/17/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 13.81 |
| 52 Week High | 31.21 |
| 52 Week Low | 9.86 |
| Avg. Daily Vol. (Mil) | 2.14 |
| Beta (3 year) | 1.59 |
| Share Related Items | |
| Mkt Cap (Mil) | 1,391.99 |
| Shares Out (Mil) | 100.72 |
| Float (Mil) | 88.52 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 4.40 |
| Current Ratio | 5.90 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 227.14 |
| Price/Book | 7.92 |
| Price/Cash Flow | -8.20 |
| Per Share Data | |
| Earnings | -1.74 |
| Sales | 0.06 |
| Book Value | 1.74 |
| Cash Flow | -1.69 |
| Business Summary | |
|---|---|
| VIVUS is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets, including obesity and related morbidities, such as sleep apnea and diabetes and men's sexual health. | |
| General Information | |
| 1172 Castro Street
Mountain View, CA 94040 |
|
| www.vivus.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 121 | |
| CEO: Leland F. Wilson | |
| Short Interest | |
| Current Month (Mil) | 30.76 |
| Previous Month (Mil) | 29.51 |
| Short Interest Ratio (Days) | 11.50 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -82.80 |
| Return on Investments | -99.00 |
| Profitability | |
| Gross Margin | 90.60 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with VVUS
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- UserMy Watch List
- ContributorStocks Rising On Unusual Vo...
- User2012 picks 10/28/20121
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- UserMy Watch
Latest VVUS Headlines from TheStreet
- Large Vivus Shareholder Seeks More Change 04.10.13 | 10:04 am
- Arena Bulls, Bears Endure Annoyingly Long Wait for Belviq Launch 04.10.13 | 09:04 am
- Vivus Piles New Debt On Top Of Excuses 03.26.13 | 10:03 am
- VIVUS Announces $110 Million Synthetic Capped Royalty Financing 03.26.13 | 06:03 am
- Vivus (VVUS): Drugs' Featured Champion Of The Day 03.21.13 | 05:03 pm
- Vivus (VVUS): Today's Featured Drugs Laggard 03.14.13 | 05:03 pm
- VIVUS Confirms Receipt Of Notice Of Nomination From First Manhattan Co. 03.08.13 | 03:03 pm
- Vivus (VVUS): Today's Featured Health Care Winner 03.07.13 | 05:03 pm
- VIVUS To Present At Three Investor Conferences In March 2013 03.04.13 | 06:03 am
- The Five Dumbest Things on Wall Street This Week: March 1 03.01.13 | 07:03 am
Press Releases for VVUS
- VIVUS Announces FDA Approval Of Qsymia REMS Modification Allowing Access Through Certified Retail Pharmacies - PR Newswire 04.16.13 | 02:04 pm
- New Obesity Education Program To Premiere At American College Of Physicians (ACP) Annual Meeting - PR Newswire 04.10.13 | 10:04 am
- Analysis In Health Economics Review Concludes Effective Medical Obesity Treatment Could Reduce Medicare Spending - PR Newswire 03.25.13 | 06:03 am
- VIVUS Launches Mobile App To Help Patients Lose Weight - PR Newswire 03.07.13 | 07:03 am
- VIVUS Announces New Qsymia Offer - PR Newswire 03.05.13 | 07:03 am
- Study Concludes That Weight Loss With Qsymiaâ¿¢ Significantly Improves Multiple Cardiovascular Disease Risk Factors - PR Newswire 02.01.13 | 07:02 am
- VIVUS Announces Express Scripts Adds Qsymia (Phentermine And Topiramate Extended-Release) Capsules CIV To Its Standard Benefits Program - PR Newswire 12.20.12 | 06:12 am
- Study Finds Significant Improvements In Patients With Obstructive Sleep Apnea Treated With Phentermine And Topiramate Extended-Release Capsules - PR Newswire 11.12.12 | 07:11 am
- VIVUS Submits REMS Amendment To FDA For Qsymia (Phentermine And Topiramate Extended-Release) Capsules CIV - PR Newswire 10.17.12 | 07:10 am
- Express Scripts Joins Qsymia⢠(Phentermine And Topiramate Extended-Release) Certified Home Delivery Pharmacy Network - PR Newswire 10.08.12 | 07:10 am
Partner Headlines for VVUS
- A Look At 3 Obesity Stocks - Seeking Alpha 03.05.13 | 09:03 am
- UPDATE: JP Morgan Cuts PT to $22 on VIVUS Following Q4 Report - Benzinga 02.26.13 | 09:02 am
- Arena's Recent Outperform Call And A Probability Weighted Valuation - Seeking Alpha 02.08.13 | 08:02 am
- Novo Nordisk Earnings Beat Views; Competition Looms - Investor's Business Daily 01.31.13 | 04:01 pm
- Orexigen: The Best Bet In Obesity For 2013 - Seeking Alpha 12.17.12 | 09:12 am
- Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX) - Benzinga 11.12.12 | 01:11 pm
- Vivus Reports A Weak 1st Quarter For Qsymia - Seeking Alpha 11.08.12 | 09:11 am
- Vivus Reports Earnings And Initial Results Of Qsymia Sales - Seeking Alpha 11.06.12 | 09:11 am
- Vivus Gets Expected European Rejection - Seeking Alpha 10.19.12 | 09:10 am
- The right data is key to spotting trends - NASDAQ 09.21.12 | 02:09 pm
